REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Hitgen Inc. (成都先导药物开发股份有限公司) (China)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Hitgen Inc. Profile Updated: December 08, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English & Chinese Download a sample report

Hitgen Inc. is in the business of innovative drug discovery. The company provides DNA Encoded Library and screening technology for the R&D of drugs on major diseases such as oncology, cardiovascular, respiratory and metabolism etc. The company was established in 2012, headquartered in Chengdu City, China.

Headquarters
Tianfu International Biological City, Chengdu, Sichuan Province (No. 18, Section 2, Middle Biological City Road, Shuangliu District)
Chengdu; Sichuan; Postal Code: 610200

Contact Details: Purchase the Hitgen Inc. (成都先导药物开发股份有限公司) report to view the information.

Website: http://www.hitgen.com

Basic Information
Total Employees:
Purchase the Hitgen Inc. (成都先导药物开发股份有限公司) report to view the information.
Outstanding Shares:
Purchase the Hitgen Inc. (成都先导药物开发股份有限公司) report to view the information.
Registered Capital:
Purchase the Hitgen Inc. (成都先导药物开发股份有限公司) report to view the information.
Financial Auditors:
Purchase the Hitgen Inc. (成都先导药物开发股份有限公司) report to view the information.
Incorporation Date:
February 22, 2012
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Chairman of the Supervisory Board
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Ownership Details
Purchase this report to view the information.
20.43%
Purchase this report to view the information.
12.82%
Purchase this report to view the information.
9.65%
Purchase this report to view the information.
6.6%
Purchase this report to view the information.
4.1%
Subsidiaries
Chengdu Kehui Leading Pharmaceutical R&D Co., Ltd.
100%
Chengdu Pilot Nucleic Acid Biotechnology Co., Ltd.
100%
Chongqing Lead Protein Technology Co., Ltd.
100%
Company Performance
Financial values in the chart are available after Hitgen Inc. (成都先导药物开发股份有限公司) report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency CNY. Absolute financial data is included in the purchased report.
Net sales revenue
23.98%▲
Total operating revenue
21.69%▲
Operating profit (EBIT)
296.32%▲
Net Profit (Loss) for the Period
220.1%▲
Total assets
12.37%▲
Total equity
6.93%▲
Operating Profit Margin (ROS)
19.16%▲
Net Profit Margin
15.2%▲
Return on Equity (ROE)
4.08%▲
Debt to Equity Ratio
-1.77%▼
Quick Ratio
-11.03%▼
Cash Ratio
-3.79%▼

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo